Evolving Concepts in Sepsis Definitions

Critical Care Clinics

Volumn 25, Issue 4, 2009, Pages 665-675

  Vincent, Jean Louis ^a   Martinez, Eva Ocampos ^a   Silva, Eliezer ^b  

^a ERASME HOSPITAL   (Belgium)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Diagnosis; Infection; PIRO; Sepsis; Septic shock

Indexed keywords

CLINICAL FEATURE; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SYMPTOMATOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANTI-BACTERIAL AGENTS; COMORBIDITY; HEALTH STATUS INDICATORS; HEMODYNAMICS; HUMANS; MULTIPLE ORGAN FAILURE; PROGNOSIS; RISK ASSESSMENT; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 70350502822     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2009.07.001     Document Type: Review

References (28)

1. Poeze M., Ramsay G., Gerlach H., et al. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care 8 (2004) R409-R413
2. Geroulanos S., and Douka E.T. Historical perspective of the word "sepsis". [letter]. Intensive Care Med 32 (2006) 2077
3. Schottmueller H. Nature and Management of sepsis. Inn Med 31 (1914) 257-280
4. Bone R.C., Fisher C.J., Clemmer T.P., et al. Sepsis syndrome: a valid clinical entity. Crit Care Med 17 (1989) 389-393
5. Bone R.C., Fisher C.J., Clemmer T.P., et al. The methylprednisolone severe sepsis study group: a controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317 (1987) 653-658
6. Panacek E.A., Marshall J.C., Albertson T.E., et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32 (2004) 2173-2182
7. ACCP-SCCM Consensus Conference: definitions of sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (1992) 864-874
8. Trzeciak S., Zanotti-Cavazzoni S., Parrillo J.E., et al. Inclusion criteria for clinical trials in sepsis: did the American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of sepsis have an impact?. Chest 127 (2005) 242-245
9. Veloso T., Neves A.P., and Vincent J.L. Are the concepts of SIRS and MODS useful in sepsis?. In: Deutschman C.S., and Neligan P.J. (Eds). The evidence based practice of critical care (2009), Elsevier, New York in press
10. Napolitano L.M., Ferrer T., McCarter Jr. R.J., et al. Systemic inflammatory response syndrome score at admission independently predicts mortality and length of stay in trauma patients. J Trauma 49 (2000) 647-652
11. Malone D.L., Kuhls D., Napolitano L.M., et al. Back to basics: validation of the admission systemic inflammatory response syndrome score in predicting outcome in trauma. J Trauma 51 (2001) 458-463
12. Sprung C.L., Sakr Y., Vincent J.L., et al. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely ill Patients (SOAP) study. Intensive Care Med 32 (2006) 421-427
13. Vincent J.L. Dear sirs, I'm sorry to say that I don't like you. Crit Care Med 25 (1997) 372-374
14. Pittet D., Rangel-Frausto S., Li N., et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21 (1995) 302-309
15. Rangel Frausto M.S., Pittet D., Costigan M., et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 (1995) 117-123
16. Bossink A.W., Groeneveld J., Hack C.E., et al. Prediction of mortality in febrile medical patients: how useful are systemic inflammatory response syndrome and sepsis criteria?. Chest 113 (1998) 1533-1541
17. Vincent J.L., de Mendonca A., Cantraine F., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 26 (1998) 1793-1800
18. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003) 1250-1256
19. Marshall J.C. Rethinking sepsis: from concepts to syndromes to diseases. Sepsis 3 (1999) 5-10
20. Marshall J.C. Sepsis research: where have we gone wrong?. Crit Care Resusc 8 (2006) 241-243
21. Carlet J., Cohen J., Calandra T., et al. Sepsis: time to reconsider the concept. Crit Care Med 36 (2008) 964-966
22. Denoix P. Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg 1 (1946) 70-75
23. Moreno R.P., Metnitz B., Adler L., et al. Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med 34 (2008) 496-504
24. Lisboa T., Diaz E., Sa-Borges M., et al. The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest 134 (2008) 1208-1216
25. Rello J., Rodriguez A., Lisboa T., et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 37 (2009) 456-462
26. Rubulotta F., Marshall J.C., Ramsay G., et al. Predisposition, insult/infection, response, and organ dysfunction: a new model for staging severe sepsis. Crit Care Med 37 (2009) 1329-1335
27. Sobin L.H., and Wittekind C. TNM classification of malignant tumours. 6th edition (2002), Wiley, Hoboken (NJ)
28. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709